Myocardial efficiency in heart failure: Non invasive imaging

Heart and Metabolism

Volumn , Issue 39, 2008, Pages 14-19

  Knaapen, Paul ^a,b   Germans, Tjeerd ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Clinical; Efficiency; Myocardium; Non invasive measurement; Work

Indexed keywords

AEROBIC METABOLISM; CARDIOMYOPATHY; ELECTROMAGNETIC FLOWMETER; HEART CATHETERIZATION; HEART FAILURE; PRIORITY JOURNAL; REVIEW;

EID: 49949101672     PISSN: 15660338     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Braunwald E. Control of myocardial oxygen consumption: physiologic and clinical considerations. Am J Cardiol. 1971;27:416-432.
2. Bing RJ, Hammond M, Handelsman JC, et al. The measurement of coronary blood flow, oxygen consumption, and efficiency of the left ventricle in man. Am Heart J. 1949;38:1-24.
3. Suga H. Ventricular energetics. Physiol Rev. 1990;70:247-277.
4. Katz AM. Cardiomyopathy of overload. A major determinant of prognosis in congestive heart failure. N Engl J Med. 1990;322:100-110.
5. Ingwall JS, Weiss RG. Is the failing heart energy starved? On using chemical energy to support cardiac function. Circ Res. 2004;95:135-145.
6. Eichhorn EJ, Bristow MR. Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure. Circulation. 1996;94:2285-2296.
7. Fick A. Über die Messung den Blutquantums in der Herzventrikeln. Sitzungb Phys Med Ces Würzburg. 1870;16.
8. Knaapen P, Germans T, Knuuti J, et al. Myocardial energetics and efficiency: current status of the noninvasive approach. Circulation. 2007;115:918-927.
9. Gibbs CL. Cardiac energetics. Physiol Rev. 1978;58:174-254.
10. Gropler RJ. Noninvasive measurements of myocardial oxygen consumption - can we do better? J Am Coll Cardiol. 2003;41:468-470.
11. Klein LJ, Visser FC, Knaapen P, et al. Carbon-11 acetate as a tracer of myocardial oxygen consumption. Eur J Nucl Med. 2001;28:651-668.
12. Armbrecht JJ, Buxton DB, Schelbert HR. Validation of [1-11C]acetate as a tracer for noninvasive assessment of oxidative metabolism with positron emission tomography in normal, ischemic, postischemic, and hyperemic canine myocardium. Circulation. 1990;81:1594-1605.
13. Schulz R, Kappeler C, Coenen H, Bockisch A, Heusch G. Positron emission tomography analysis of [1-(11)C] acetate kinetics in short-term hibernating myocardium. Circulation. 1998;97:1009-1016.
14. Sun KT, Yeatman LA, Buxton DB, et al. Simultaneous measurement of myocardial oxygen consumption and blood flow using [1-carbon-11]acetate. J Nucl Med. 1998;39:272-280.
15. Bellenger NG, Burgess Ml, Ray SG, et al. Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable? Eur Heart J. 2000;21:1387-1396.
16. Kelly RP, Ting CT, Yang TM, et al. Effective arterial elastance as index of arterial vascular load in humans. Circulation. 1992;86:513-521.
17. Currie PJ, Seward JB, Reeder GS, et al. Continuous-wave Doppler echocardiographic assessment of severity of calcific aortic stenosis: a simultaneous Doppler-catheter correlative study in 100 adult patients. Circulation. 1985;71:1162-1169.
18. Bouchard A, Blumlein S, Schiller NB, et al. Measurement of left ventricular stroke volume using continuous wave Doppler echocardiography of the ascending aorta and M-mode echocardiography of the aortic valve. J Am Coll Cardiol. 1987;9:75-83.
19. Rebergen SA, van der Wall EE, Doornbos J, de Roos A. Magnetic resonance measurement of velocity and flow: technique, validation, and cardiovascular applications. Am Heart J. 1993;126:1439-1456.
20. Beanlands RS, Bach DS, Raylman R, et al. Acute effects of dobutamine on myocardial oxygen consumption and cardiac efficiency measured using carbon-11 acetate kinetics in patients with dilated cardiomyopathy. J Am Coll Cardiol. 1993;22:1389-1398.
21. Neubauer S, Horn M, Cramer M, et al. Myocardial phosphocreatine-to-ATP ratio isa predictorof mortality in patients with dilated cardiomyopathy. Circulation. 1997;96:2190-2196.
22. De Sousa E, Veksler V, Minajeva A, et al. Subcellular creatine kinase alterations. Implications in heart failure. Circ Res. 1999;85:68-76.
23. Recchia FA, McConnell PI, Bernstein RD, Vogel TR, Xu X, Hintze TH. Reduced nitric oxide production and altered myocardial metabolism during the decompensation of pacing-induced heart failure in the conscious dog. Circ Res. 1998;83:969-979.
24. Sawyer DB, Colucci WS. Mitochondrial oxidative stress in heart failure: "oxygen wastage" revisited. Circ Res. 2000;86:119-120.
25. Knaapen P, Götte MJ, Paulus WJ, et al. Does myocardial fibrosis hinder contractile function and perfusion in idiopathic dilated cardiomyopathy? A PET and MRI study. Radiology. 2006;240:380-388.
26. Kim IS, Izawa H, Sobue T, et al. Prognostic value of mechanical efficiency in ambulatory patients with idiopathic dilated cardiomyopathy in sinus rhythm. J Am Coll Cardiol. 2002;39:1264-1268.
27. Vanoverschelde JL, Wijns W, Essamri B, et al. Hemodynamic and mechanical determinants of myocardial O2 consumption in normal human heart: effects of dobutamine. Am J Physiol Heart Circ Physiol. 1993;265:H1884-H1892.
28. Hayashi Y, Takeuchi M, Takaoka H, Hata K, Mori M, Yokoyama M. Alteration in energetics in patients with left ventricular dysfunction after myocardial infarction: increased oxygen cost of contractility. Circulation. 1996;93:932-939.
29. Porenta G, Cherry S, Czernin J, et al. Noninvasive determination of myocardial blood flow, oxygen consumption and efficiency in normal humans by carbon-11 acetate positron emission tomography imaging. Eur J Nucl Med. 1999;26:1465-1474.
30. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med. 1991;325:1468-1475.
31. O'Connor CM, Gattis WA, Uretsky BF, et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1999;138:78-86.
32. Braunwald E, Bristow MR. Congestive heart failure: fifty years of progress. Circulation. 2000;102:IV14-IV23.
33. Massie BM. 15 years of heart-failure trials: what have we learned? Lancet. 1998;352 (suppl 1):SI29-SI33.
34. Wolpers HG, Buck A, Nguyen N, et al. An approach to ventricular efficiency by use of carbon 11-labeled acetate and positron emission tomography. J Nucl Cardiol. 1994;1:262-269.
35. Hall SA, Cigarroa CG, Marcoux L, Risser RC, Grayburn PA, Eichhorn EJ. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol. 1995;25:1154-1161.
36. Eichhorn EJ, Heesch CM, Barnett JH, et al. Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 1994;24:1310-1320.
37. Beanlands RS, Nahmias C, Gordon E, et al. The effects of beta(1)-blockade on oxidative metabolism and the metabolic cost of ventricular work in patients with left ventricular dysfunction: A double-blind, placebo-controlled, positronemission tomography study. Circulation. 2000;102:2070-2075.